Filing Details

Accession Number:
0000947871-15-000885
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-12-23 17:06:03
Reporting Period:
2015-12-21
Filing Date:
2015-12-23
Accepted Time:
2015-12-23 17:06:03
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1416792 Relypsa Inc RLYP Pharmaceutical Preparations (2834) 260893742
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1055949 D Samuel Isaly 601 Lexington Avenue, 54Th Floor
New York NY 10022
No No Yes No
1055951 Orbimed Advisors Llc 601 Lexington Avenue, 54Th Floor
New York NY 10022
No No Yes No
1502240 Orbimed Capital Gp Iv Llc 601 Lexington Avenue, 54Th Floor
New York NY 10022
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2015-12-21 235,829 $27.50 7,664,171 No 4 S Indirect See Footnotes
Common Stock Disposition 2015-12-21 14,171 $28.39 7,650,000 No 4 S Indirect See Footnotes
Common Stock Disposition 2015-12-22 111,370 $26.39 7,538,630 No 4 S Indirect See Footnotes
Common Stock Disposition 2015-12-22 38,630 $27.02 7,500,000 No 4 S Indirect See Footnotes
Common Stock Disposition 2015-12-23 47,942 $26.78 7,452,058 No 4 S Indirect See Footnotes
Common Stock Disposition 2015-12-23 52,058 $27.54 7,400,000 No 4 S Indirect See Footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares of the Issuer's common stock ("Shares") were sold in multiple transactions at prices ranging from $27.01 to $28.00, inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission (the "SEC") full information regarding the Shares sold at each separate price within the range set forth in this footnote.
  2. The price reported in Column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $28.01 to $28.75, inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the Shares sold at each separate price within the range set forth in this footnote.
  3. The price reported in Column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $25.88 to $26.87, inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the Shares sold at each separate price within the range set forth in this footnote.
  4. The price reported in Column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $26.88 to $27.65, inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the Shares sold at each separate price within the range set forth in this footnote.
  5. The price reported in Column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $26.25 to $27.24, inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the Shares sold at each separate price within the range set forth in this footnote.
  6. The price reported in Column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $27.25 to $27.79, inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the Shares sold at each separate price within the range set forth in this footnote.
  7. These Shares are held of record by OrbiMed Private Investments IV, LP ("OPI IV"). OrbiMed Capital GP IV LLC ("GP IV") is the sole general partner of OPI IV. OrbiMed Advisors LLC ("Advisors"), a registered adviser under the Investment Advisers Act of 1940, as amended, is the sole managing member of GP IV. Samuel D. Isaly ("Isaly") is the managing member of and owner of a controlling interest in Advisors. By virtue of such relationships, GP IV, Advisors and Isaly may be deemed to have voting and investment power over the Shares held of record by OPI IV and as a result may be deemed to have beneficial ownership over such Shares.
  8. This Form 4 is jointly filed by GP IV, Advisors and Isaly. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of them are beneficial owners for the purpose of Section 16 of the Exchange Act, or for any other purpose.